blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2626704

EP2626704 - DIAGNOSIS OF PANCREATIC DIABETES IN PATIENTS WITH NORMAL BLOOD LEUCOCYTE COUNTS USING PROCALCITONIN [Right-click to bookmark this link]
Former [2013/33]Diagnosis and complication risk assessment of pancreatic diabetes within normal value ranges of leucocytes using procalcitonin
[2015/29]
StatusNo opposition filed within time limit
Status updated on  23.09.2016
Database last updated on 18.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Soylemez, Mehmet Ali
Neyzenbasi Halil Can Sk. Sadibey Apt. 48/8
Salacak-Uskudar
34668 Istanbul / TR
[2013/33]
Inventor(s)01 / see applicant
...
 [2013/33]
Application number, filing date12154587.508.02.2012
[2013/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2626704
Date:14.08.2013
Language:EN
[2013/33]
Type: B1 Patent specification 
No.:EP2626704
Date:18.11.2015
Language:EN
[2015/47]
Search report(s)(Supplementary) European search report - dispatched on:EP19.09.2012
ClassificationIPC:G01N33/68
[2013/33]
CPC:
G01N33/6893 (EP); G01N2333/585 (EP); G01N2800/042 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/47]
Former [2013/33]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DIAGNOSE VON BAUCHSPEICHELDRÜSEN DIABETES BEI PATIENTEN MIT NORMALEN BLUT LEUKOZYTENZAHLEN UNTER VERWENDUNG VON PROCALCITONIN[2015/29]
English:DIAGNOSIS OF PANCREATIC DIABETES IN PATIENTS WITH NORMAL BLOOD LEUCOCYTE COUNTS USING PROCALCITONIN[2015/40]
French:DIAGNOSTIC DU DIABÈTE PANCRÉATIQUE CHEZ LES PATIENTS AVEC LES VALEURS NORMALES DE LEUCOCYTES SANGUINS EN UTILISANT LA PROCALCITONINE[2015/29]
Former [2013/33]Diagnose und Komplikationen Risikobewertung von Diabetes Mellitus in der Normal-Wertebereiche Leukozyten Verwendung Procalcitonin
Former [2013/33]Diagnosis and complication risk assessment of pancreatic diabetes within normal value ranges of leucocytes using procalcitonin
Former [2013/33]Le diagnostic et evaluation des risques complication du diabète pancreatique dans les valeurs normales de leucocytes en utilisant la procalcitonine
Examination procedure08.02.2012Loss of particular rights, legal effect: Priority
05.06.2012Despatch of communication of loss of particular rights: Priority 0001
08.01.2013Amendment by applicant (claims and/or description)
16.01.2013Examination requested  [2013/33]
11.12.2013Despatch of a communication from the examining division (Time limit: M04)
15.12.2013Reply to a communication from the examining division
11.07.2014Despatch of a communication from the examining division (Time limit: M04)
18.07.2014Reply to a communication from the examining division
08.05.2015Despatch of a communication from the examining division (Time limit: M04)
15.05.2015Reply to a communication from the examining division
24.06.2015Communication of intention to grant the patent
15.07.2015Fee for grant paid
15.07.2015Fee for publishing/printing paid
17.07.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.09.2015Communication of intention to grant the patent
11.09.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.09.2015Communication of intention to grant the patent
02.10.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  11.12.2013
Opposition(s)19.08.2016No opposition filed within time limit [2016/43]
Fees paidRenewal fee
29.04.2014Renewal fee patent year 03
28.01.2015Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
28.02.201403   M06   Fee paid on   29.04.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.02.2012
AL18.11.2015
AT18.11.2015
BE18.11.2015
BG18.11.2015
CY18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
MK18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
MT29.02.2016
IS18.03.2016
PT18.03.2016
[2018/46]
Former [2018/38]HU08.02.2012
AT18.11.2015
BE18.11.2015
BG18.11.2015
CY18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
MK18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
MT29.02.2016
IS18.03.2016
PT18.03.2016
Former [2018/31]HU08.02.2012
AT18.11.2015
BE18.11.2015
CY18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
MK18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
MT29.02.2016
IS18.03.2016
PT18.03.2016
Former [2018/28]HU08.02.2012
AT18.11.2015
BE18.11.2015
CY18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
MK18.11.2015
MT18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2017/47]AT18.11.2015
BE18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
MT18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2017/03]AT18.11.2015
BE18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/49]AT18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SI18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/42]AT18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
MC18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/38]AT18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SK18.11.2015
SM18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/36]AT18.11.2015
CZ18.11.2015
EE18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
NL18.11.2015
PL18.11.2015
RO18.11.2015
RS18.11.2015
SK18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/34]AT18.11.2015
CZ18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
NL18.11.2015
PL18.11.2015
RS18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/30]AT18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
NL18.11.2015
PL18.11.2015
RS18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/25]AT18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
LV18.11.2015
PL18.11.2015
RS18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/24]AT18.11.2015
ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
PL18.11.2015
RS18.11.2015
GR19.02.2016
IS18.03.2016
PT18.03.2016
Former [2016/23]ES18.11.2015
HR18.11.2015
IT18.11.2015
LT18.11.2015
RS18.11.2015
IS18.03.2016
Former [2016/22]ES18.11.2015
IT18.11.2015
LT18.11.2015
IS18.03.2016
Former [2016/21]ES18.11.2015
IT18.11.2015
LT18.11.2015
Former [2016/20]ES18.11.2015
LT18.11.2015
Documents cited:Search[XDA]  - M.A. STOYLEMEZ, "Procalcitonin is a specific marker of diabetic complication process", EUROPEAN JOURNAL OF HUMAN GENETICS, Gothenburg, Sweden, (20100612), vol. 18, no. suppl 1, page 352, XP055037335 [XD] 14 * the whole document * [A] 1-13
 [XDA]  - SOYLEMEZ ET AL, "A Novel Mechanism between Diabetes Mellitus Complications and Procalcitonin Gene Expression", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, USA, American Society of Gene & Cell Therapy 555 East Wells Street Suite 1100 Milwaukee, WI 53202 USA, (20060101), vol. 13, ISSN 1525-0016, page S86, XP005675332 [XD] 14 * page S86, column 2, section "Results" * [A] 1-13
 [AD]  - SOYLEMEZ ET AL, "894. A Novel Mechanism between Type II Diabetes Mellitus and Procalcitonin Gene Expression", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, USA, American Society of Gene & Cell Therapy 555 East Wells Street Suite 1100 Milwaukee, WI 53202 USA, (20050815), vol. 11, ISSN 1525-0016, page 346, XP005016233 [AD] 1-14 * the whole document *
 [A]  - ABBASI A ET AL, "Plasma procalcitonin and risk of type 2 diabetes in the general population", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, (20110615), vol. 54, no. 9, doi:10.1007/S00125-011-2216-3, ISSN 1432-0428, pages 2463 - 2465, XP019934333 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00125-011-2216-3
 [A]  - MESUT MUTLUOLU ET AL, "Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study", DIABETES RESEARCH AND CLINICAL PRACTICE, AMSTERDAM, NL, vol. 94, no. 1, doi:10.1016/J.DIABRES.2011.05.023, ISSN 0168-8227, (20110516), pages 53 - 56, (20110519), XP028323696 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.diabres.2011.05.023
ExaminationUS2011263438
by applicant   - MEHMET A. SOYLEMEZ ET AL., "A Novel Mechanism between Type II Diabetes Mellitus and Procalcitonin Gene Expression", MOLECULAR THERAPY, (2005), vol. 11, page 3461
    - MEHMET A. SOYLEMEZ ET AL., "Novel Mechanism between Diabetes Mellitus Complications and Procalcitonin Gene Expression", MOLECULAR THERAPY, (2006), vol. 13, page 861
    - YUKIOKA ET AL., ANN. ACAD. MED. SINGAPORE, (2001), vol. 30, pages 528 - 31
    - KARZAI ET AL., "Procalcitonin-A New Indicator of the Systemic Response to Severe Infections", INFECTION, vol. 25, no. 6, doi:doi:10.1007/BF01740811, pages 329 - 334, XP000879253

DOI:   http://dx.doi.org/10.1007/BF01740811
    - OTTER W.; STANDI E.; SCHNELL 0, "Inflammation and atherogenesis in diabetes mellitus-new therapeutic approaches", HERZ, (2004), vol. 29, no. 5, pages 524 - 31
    - HATHERIL M.; TIBBY SM.; SYKES K.; TURNER C.; MURDOCH, I A., "Diagnostic markers of infection: comparision of procalcitonin with C reactive protein and leucocyte count", ARCH DIS CHILD
    - OTTER W.; STANDI E.; SCHNELL 0., "Inflammation and atherogenesis in diabetes mellitus-new therapeutic approaches", HERZ, (2004), vol. 29, no. 5, pages 524 - 31
    - LE MOULLEC J. M. ET AL., "The complete sequence of human procalcitonin", FEBS LETT., (1984), vol. 167, no. 1, doi:doi:10.1016/0014-5793(84)80839-X, pages 93 - 97, XP025569943

DOI:   http://dx.doi.org/10.1016/0014-5793(84)80839-X
    - WHICHER J.; BIENVENU J.; MONNERET G., "Procalcitonin as an acute phase marker", ANN CLIN BIOCHEM., (2001), vol. 38, no. 5, pages 483 - 93
    - BECKMAN J.; CREAGER M.; LIBBY P., "Diabetes and Atherosclerosis", JAMA, (2002), vol. 287, pages 2570 - 2581
    - MEHMET ALI SOYLEMEZ ET AL., A NOVEL MECHANISM BETWEEN TYPE II DIABETES MELLITUS AND PROCALCITONIN GENE EXPRESSION MOLECULAR THERAPY, (2005), vol. 11, page 3461
    - "Control No. 2010-A-377) ESHG conference 2010 Gothenburg, Sweden", METABOLIC DISORDERS, vol. 18, no. 1, page 352,13.14
    - MATTHEWS D R; HOSKER J P; RUDENSKI A S; NAYLOR B A; TREACHER D F; TURNER R C, "Homeostasis Model Assessment: Insulin Resistance and B-cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man", DIABETOLOGIA, (1985), vol. 28, doi:doi:10.1007/BF00280883, pages 412 - 419, XP008152969

DOI:   http://dx.doi.org/10.1007/BF00280883
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.